pretickt

Is COR a good stock to buy?

Cencora, Inc. · end-of-day data as of Nov 13, 2026

Cencora
COR · $68.51B
$359.03+3.0%
Nov 13, 2026 · close
$300$320$340$360SepOctNov9:3016:003 months +13.8%Nov 13 · close
▲ 7
  • ConsensusBuy · 14
  • P/E vs own-21.8%
  • P/E vs sector-37.8%
  • FCF yield+5.7%
  • MAs4 of 4
  • MACD1.49
  • Sector▲ +15.9%
Neutral
  • Earnings in82d
  • P/E20.0x
  • RSI67
  • Support-1.6%
  • Resistance+2.6%
  • Off 52w high-4.9%
  • Volume1.0x
  • PT$364.70 +1.6%
  • Trendsideways
  • 52w range$245–$378
  • ATR+2.5%
  • Off ATH-4.9%
▼ 3
  • Insiders-$5.02M
  • News
  • Bollingerabove upper

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Cencora a good stock to buy?

Cencora is strong on 3 of the 5 questions about the business; weak on economics. The price is low: 20.0 times its earnings, below its 3-year median of 28.3 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics thin margins
  4. Execution delivers
  5. Fragility sturdy
  6. Price below its usual
DemandDo people want more of what it sells?growing

COR sales growth revenue growth

+9%a year, for the last 3 years

Cencora's sales grew 9% a year for 3 years, to $337B in fiscal 2026.

COR analysts' forecast revenue estimates

+5%the sales they expect next fiscal year, on the last

Analysts expect Cencora's sales to grow 5% to $353B in fiscal 2027 (5 analysts).

COR peers

pretickt analysis+5%its sales in 12 months, on a year before

Cencora's sales grew 5% in the 12 months to Sep 30, 2026, slower than Cardinal Health (+10%), Boston Scientific (+9%), McKesson (+8%) and Henry Schein (+6%).

Advantage moatIs it hard to copy?some edge

COR return on capital ROIC

pretickt analysis44%earned before tax on the money invested in it

Cencora earned 44% before tax on the capital invested in it in the 12 months to Sep 30, 2026; McKesson 1,000%, Cardinal Health 513%, Boston Scientific 12% and Henry Schein 11%.

COR margin on each sale gross margin

4%left after making the product

Cencora kept 4% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 17%.

EconomicsDoes it make good money?thin margins

COR margin after costs profit margin

1%of sales left after running the business

Cencora's operating margin was 1% in the 12 months to Sep 30, 2026, against 1% in fiscal 2023.

COR cash generated free cash flow

$3.88Bcash left after investing, last 12 months

Cencora generated $3.88B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

COR profit per share

+125%in its last fiscal year

Cencora's earnings per share grew 125% in fiscal 2026, to $17.92.

ExecutionDoes it deliver what it promises?delivers

COR earnings vs estimates

7 of 7quarters above the analysts' estimate

Cencora beat the analysts' profit estimate in all 7 quarters, the latest on Nov 4, 2026; 1 quarter the sources disagree on is left out.

COR insider selling

-$13.07Msold, net, by its executives in 12 months

Cencora's executives and directors sold a net $13.07M of shares in the 12 months to Nov 13, 2026 ($15.38M sold, $2.31M bought).

COR number of employees

+12%more people in a year

Cencora had 47,000 employees at the end of fiscal 2025, 12% more than a year before.

COR CEO pay

$18.26Mfor fiscal 2025, 66% of it in stock and options

Cencora paid its CEO $18.26M for fiscal 2025, 66% of it in stock and options.

Fragility risksCould something break it?sturdy

COR financial health Altman Z-score

4.5Altman Z-score, safe above 3

Cencora's Altman Z-score is 4.5 (Nov 13, 2026), above 3, where the safe zone starts.

COR quality checks Piotroski score

7 of 9checks passed

Cencora passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt and sales for its assets.

COR biggest customers

38%of sales from its 2 biggest customers

Walgreens and Boots and Evernorth Health Services made 38% of Cencora's sales in fiscal 2025.

COR in past recessions

pretickt analysis+2%its sales in the worst one

Cencora's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?below its usual

COR price vs profit P/E ratio

20.0×a year's earnings

Cencora's P/E ratio is 20.0 (Nov 13, 2026), below its 3-year median of 28.3.

COR price vs peers

pretickt analysis20.0×a year's earnings, against its peers

Investors pay 20.0 times Cencora's earnings (Nov 13, 2026), more than for Boston Scientific (18.8), less than for Cardinal Health (36.4), McKesson (28.4) and Henry Schein (23.6).

COR analysts' target price target

+2%to their average target

Analysts' average price target for Cencora is $365, 2% above the Nov 13, 2026 close of $359.03.

COR growth priced in fair value

pretickt analysis+5%a year, for ten years, to be worth the price

At $359.03 a share, Cencora's free cash flow must grow about 5% a year for ten years to be worth the price (Nov 13, 2026).

What is Cencora's P/E ratio?

Cencora's P/E ratio is 20.0 (Nov 13, 2026), below its 3-year median of 28.3. Investors pay 20.0 times Cencora's earnings (Nov 13, 2026), more than for Boston Scientific (18.8), less than for Cardinal Health (36.4), McKesson (28.4) and Henry Schein (23.6).

Is Cencora profitable?

Cencora's operating margin was 1% in the 12 months to Sep 30, 2026, against 1% in fiscal 2023. Cencora generated $3.88B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

Are insiders selling Cencora stock?

Cencora's executives and directors sold a net $13.07M of shares in the 12 months to Nov 13, 2026 ($15.38M sold, $2.31M bought).

How many employees does Cencora have?

Cencora had 47,000 employees at the end of fiscal 2025, 12% more than a year before.

Who are Cencora's biggest customers?

Walgreens and Boots and Evernorth Health Services made 38% of Cencora's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.